11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
[HTML][HTML] Molecular mechanisms and therapeutic targets for diabetic kidney disease
Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Aims The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2
diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes …
diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes …
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional … - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
[HTML][HTML] Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in short-term trials involving patients with chronic kidney disease …
reduced albuminuria in short-term trials involving patients with chronic kidney disease …
Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects
Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …
current therapies that limit CKD progression and the development of cardiovascular disease …
Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial
Background: Chronic kidney disease and type 2 diabetes are independently associated with
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …